Peregrion is a specialized CRO that supports the acceleration and de-risking of drug development programs. We help pharma companies to collect human Mass Balance and Bioavailability data as early as Phase 1/2a, using our advanced Accelerator Mass Spectrometry (AMS) technology. Founded as a spin-off of TNO, a leading research institute, Peregrion builds on 10+yrs of AMS innovation. Our mission is to drive faster, safer, and future-oriented clinical development by delivering early human ADME insights. Trusted by multiple top 20 pharmaceutical companies, our technology uses at least 100-fold lower radioactivity and delivers at least 500-fold higher analytical sensitivity than conventional methods. This means ultra-low dosing is sufficient. Studies can be added in Phase 1/2a of clinical development, saving up to 2 years in development time.